title: Dermatology update: The dawn of targeted treatment.
abstract: During the past several years, targeted therapies have significantly improved outcomes in advanced basal cell carcinoma, psoriasis, and metastatic melanoma. This article reviews how advances in our understanding of the molecular pathogenesis of these diseases led to the development of targeted therapies and how these therapies are improving outcomes. Research is ongoing to address continuing challenges of drug resistance, adverse effects, and how best to use the new medications.
authors.affiliation: Director of Medical and Inpatient Dermatology, Department of Dermatology, and Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA. E-mail: fernana6@ccf.org.
authors.forename: Anthony
authors.initials: A
authors.lastname: Fernandez
mesh_terms: D000328:Adult; D000813:Anilides / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D003879:Dermatologic Agents / Q000627:therapeutic use*; D003880:Dermatology; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D010091:Oximes / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D011565:Psoriasis / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D013449:Sulfonamides / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D000813:Anilides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001384:Azetidines; D003879:Dermatologic Agents; C538724:HhAntag691; D007093:Imidazoles; D007211:Indoles; D020381:Interleukin-17; D010091:Oximes; D010880:Piperidines; D011725:Pyridines; D011728:Pyridones; D011744:Pyrimidinones; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D000077484:Vemurafenib; C560077:trametinib; C571216:brodalumab; C549079:ixekizumab; C555450:secukinumab; D048493:Proto-Oncogene Proteins B-raf; C574276:cobimetinib; D000069549:Ustekinumab; D000068800:Etanercept; C561627:dabrafenib